Lv4
540 积分 2024-12-10 加入
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
3个月前
已完结
Mazdutide versus placebo in Chinese adults with type 2 diabetes
3个月前
已完结
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
4个月前
已完结
Effect of tirzepatide on blood pressure and lipids: A meta‐analysis of randomized controlled trials
5个月前
已完结
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
6个月前
已完结
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
6个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
7个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
7个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
7个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
7个月前
已完结
皖公网安备34019202002308
